Your browser doesn't support javascript.
loading
Do HPV 16 positive/ASC-H cervical cancer screening results predict CIN 2+ better than other high-risk HPV subtypes?
Tokalioglu, Abdurrahman Alp; Alci, Aysun; Oktar, Okan; Ünsal, Mehmet; Yalçin, Necim; Aytekin, Okan; Çelik, Fatih; Tiryaki Güner, Gülsah; Ersak, Burak; Kiliç, Fatih; Ayhan, Sevgi; Akar Inan, Serra; Çakir, Caner; Yalçin, Hakan; Korkmaz, Vakkas; Koç, Sevgi; Boran, Nurettin; Kimyon Cömert, Günsu; Toptas, Tayfun; Üreyen, Isin; Türkmen, Osman; Moraloglu Tekin, Özlem; Erdogan, Fazli; Engin-Üstün, Yaprak; Turan, Taner.
Afiliação
  • Tokalioglu AA; Clinic of Gynecologic Oncology, University of Health Sciences Turkey, Ankara City Hospital, Ankara, Turkey.
  • Alci A; Clinic of Gynecologic Oncology, University of Health Sciences Turkey, Antalya Training and Research Hospital, Antalya, Turkey.
  • Oktar O; Clinic of Gynecologic Oncology, University of Health Sciences Turkey, Etlik Zübeyde Hanim Women's Health Training and Research Hospital, Ankara, Turkey.
  • Ünsal M; Clinic of Gynecologic Oncology, University of Health Sciences Turkey, Ankara City Hospital, Ankara, Turkey.
  • Yalçin N; Clinic of Gynecologic Oncology, University of Health Sciences Turkey, Antalya Training and Research Hospital, Antalya, Turkey.
  • Aytekin O; Clinic of Gynecologic Oncology, University of Health Sciences Turkey, Ankara City Hospital, Ankara, Turkey.
  • Çelik F; Clinic of Gynecologic Oncology, University of Health Sciences Turkey, Ankara City Hospital, Ankara, Turkey.
  • Tiryaki Güner G; Clinic of Gynecologic Oncology, University of Health Sciences Turkey, Ankara City Hospital, Ankara, Turkey.
  • Ersak B; Clinic of Gynecologic Oncology, University of Health Sciences Turkey, Ankara City Hospital, Ankara, Turkey.
  • Kiliç F; Clinic of Gynecologic Oncology, University of Health Sciences Turkey, Ankara City Hospital, Ankara, Turkey.
  • Ayhan S; Clinic of Gynecologic Oncology, University of Health Sciences Turkey, Ankara City Hospital, Ankara, Turkey.
  • Akar Inan S; Clinic of Gynecologic Oncology, University of Health Sciences Turkey, Ankara City Hospital, Ankara, Turkey.
  • Çakir C; Clinic of Gynecologic Oncology, University of Health Sciences Turkey, Etlik Zübeyde Hanim Women's Health Training and Research Hospital, Ankara, Turkey.
  • Yalçin H; Clinic of Gynecologic Oncology, University of Health Sciences Turkey, Ankara City Hospital, Ankara, Turkey.
  • Korkmaz V; Clinic of Gynecologic Oncology, University of Health Sciences Turkey, Etlik Zübeyde Hanim Women's Health Training and Research Hospital, Ankara, Turkey.
  • Koç S; Clinic of Gynecologic Oncology, University of Health Sciences Turkey, Etlik Zübeyde Hanim Women's Health Training and Research Hospital, Ankara, Turkey.
  • Boran N; Clinic of Gynecologic Oncology, University of Health Sciences Turkey, Etlik Zübeyde Hanim Women's Health Training and Research Hospital, Ankara, Turkey.
  • Kimyon Cömert G; Clinic of Gynecologic Oncology, University of Health Sciences Turkey, Ankara City Hospital, Ankara, Turkey.
  • Toptas T; Clinic of Gynecologic Oncology, University of Health Sciences Turkey, Antalya Training and Research Hospital, Antalya, Turkey.
  • Üreyen I; Clinic of Gynecologic Oncology, University of Health Sciences Turkey, Antalya Training and Research Hospital, Antalya, Turkey.
  • Türkmen O; Clinic of Gynecologic Oncology, University of Health Sciences Turkey, Ankara City Hospital, Ankara, Turkey.
  • Moraloglu Tekin Ö; Clinic of Obstetrics and Gynecology, University of Health Sciences Turkey, Ankara City Hospital, Ankara, Turkey.
  • Erdogan F; Clinic of Pathology, Ankara Yildirim Beyazit University, Ankara City Hospital, Ankara, Turkey.
  • Engin-Üstün Y; Clinic of Obstetrics and Gynecology, University of Health Sciences Turkey, Etlik Zübeyde Hanim Women's Health Training and Research Hospital, Ankara, Turkey.
  • Turan T; Clinic of Gynecologic Oncology, University of Health Sciences Turkey, Ankara City Hospital, Ankara, Turkey.
J Turk Ger Gynecol Assoc ; 25(2): 90-95, 2024 Jun 13.
Article em En | MEDLINE | ID: mdl-38868461
ABSTRACT

Objective:

To determine whether patients with atypical squamous cells, cannot exclude high grade squamous intraepithelial neoplasia (ASC-H) cytology have a correlation between high-risk human papillomavirus (HPV) type and CIN 2+1 lesion in final pathology. Material and

Methods:

The study was conducted retrospectively, using data from three tertiary gynecologic oncology centers located in various regions of Turkey. Data from 5,271 patients who had colposcopy between January 2003 and January 2021 were analyzed.

Results:

A total of 163 patients who had ASC-H cervical cytology test results, based on the Bethesda 2014 classification were eligible, and of these 83 (50.9%) who tested positive for HPV were included in the study. There was no correlation between the occurrence of CIN 2+ lesions and age (p=0.053). If there was any HPV 16 positivity (only HPV 16, HPV 16 and 18, HPV 16 and others) the presence of CIN 2+ lesions in the final pathology increased significantly. In HPV 16 positive ASC-H patients, the probability of CIN 2+ lesions in the final pathology were 72.5% while this rate was 48.1% in HPV 16 negative group (p=0.033).

Conclusion:

The guidelines do not provide a comprehensive definition of the role of the HPV test in managing ASC-H. Positive high-risk HPV types, especially HPV 16, together with an ASC-H smear result should bring to mind the possibility of high-grade dysplasia.
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2024 Tipo de documento: Article